Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 杨明明教授 (肿瘤学系) |
| 陈林教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1111/j.1440-1746.2012.07096.x |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/41WOS source URL
Scopushttp://aims.cuhk.edu.hk/converis/portal/Publication/45Scopus source URL
其它资讯
摘要Following the encouraging results of sorafenib in advanced hepatocellular carcinoma (HCC), targeted therapy has become a new direction of research in the treatment of HCC. Emerging data provide evidence that the pathogenesis and progression of HCC are mediated by a number of molecular defects and dysregulated pathways. Novel targeted therapies are designed to inhibit the aberrant pathways at a molecular level with an aim to improve the clinical outcome. For the past few years, an increasing number of targeted agents have been tested in HCC in the clinical setting. This review aims to summarize the current status of clinical development of targeted therapy in HCC, with focus on novel agents targeting angiogenesis, signal transduction and epigenetic dysregulation of tumors. The review also discusses the lessons learned from outcomes of completed clinical trials and provides perspectives on future clinical trials in HCC. ? 2012 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.
着者Chan S.L., Yeo W.
期刊名称Journal of Gastroenterology and Hepatology
出版年份2012
月份1
日期1
卷号27
期次5
出版社Blackwell Publishing Inc.
出版地United Kingdom
页次862 - 872
国际标準期刊号0815-9319
电子国际标準期刊号1440-1746
语言英式英语
关键词Biologic, Hepatocellular carcinoma, Review, Treatment
